Telo Genomics Receives New Client Tier under Intellectual Property Ontario (IPON)

Rhea-AI Summary

Telo Genomics (TSXV: TELO) (OTCQB: TDSGF) has secured an enhanced client agreement with Intellectual Property Ontario (IPON). The company has qualified for a 2nd Tier client designation, increasing its IP funding access to $100,000 per fiscal year with a $300,000 lifetime cap, up from the previous $80,000 limit. Telo currently maintains a portfolio of 23 patents and pending applications across Canada, US, and Europe, with 20 fully granted. These patents cover their core 3D telomere technology TeloView and specific applications in hematological disorders, Alzheimer's disease, and liquid biopsy technology. The company is developing diagnostic and prognostic tests for Multiple Myeloma, Minimal Residual Disease, early-stage Alzheimer's disease, and prostate cancer. Their flagship TeloViewSMM test for smoldering myeloma is expected to have patent protection until 2043.

Positive

• Increased IP funding access to $100,000 per year with $300,000 lifetime cap
• Strong IP portfolio with 23 patents/applications, 20 already granted
• Patent protection for TeloViewSMM test extends until 2043
• Access to additional benefits including training and advisory services

Negative

• None.

Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, is pleased to announce that it has entered a new client agreement with Intellectual Property Ontario (IPON).

IPON supports Ontario-based enterprises in securing and expanding their intellectual property (IP) portfolios. Telo announced on November 19, 2024, that it was accepted into the program and was allowed access of up to $80,000 of reimbursement for its prospective IP costs in addition to benefits such as training, advisory services and special rates for innovation events.

Telo has now qualified for a new 2^nd Tier client designation. As a result, Telo now has access to IP funding of up to $100,000 per fiscal year, with a lifetime cap of $300,000.

IPON has the potential to provide commercial benefits to Telo Genomics as it continues advancing its suite of prognostic assays for high-impact indications in Multiple Myeloma, Minimal Residual Disease (MRD), early-stage Alzheimer's disease, and prostate cancer. The funding and support from IPON will bolster Telo's efforts to scale its IP assets, enhance patent strategies, and attract global commercialization partners.

Telo Genomics holds an IP patent portfolio of 23 patents and pending patent applications in Canada, US and Europe. The portfolio includes patents that govern its core 3D telomere technology TeloView, and disease/ application specific patents including hematological disorders, Alzheimer's disease and circulating tumor cells (liquid biopsy) technology. Twenty out of the twenty-three patents are fully granted.

"We are grateful for the support shown by Intellectual Property Ontario." said Guido Baechler, Telo's Executive Chairman. "We continue to align our technology development and our IP strategy to expand the TeloView portfolio and its value proposition. In 2025, we are expecting the national phase entry of our smoldering myeloma filings, protecting our flagship TeloViewSMM test until 2043."

About Telo Genomics

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.

Intellectual Property Ontario  

Intellectual Property Ontario (IPON) is a provincial agency that provides trusted IP support and services to enable Ontario businesses and researchers to innovate and grow. IPON works directly with innovators and postsecondary institutions to help them better understand how to protect and maximize the value of their IP, strengthen their capacity to grow and compete in the market, and advance the province's economic growth. For more information, visit www.ip-ontario.ca.  

For further information, please contact:

Guido Baechler
Executive Chairman
416-673-8487
info@telodx.com

MaRS Centre, South Tower
101 College Street, Suite 200
Toronto, ON, M5G 1L7
www.telodx.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's receipt of TSXV acceptance of the stock option grant are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253422

FAQ

What is the new funding amount TDSGF received from Intellectual Property Ontario?

Telo Genomics qualified for IPON's 2nd Tier client designation, increasing IP funding access to $100,000 per fiscal year with a $300,000 lifetime cap.

How many patents does Telo Genomics currently hold in its portfolio?

Telo Genomics holds 23 patents and pending patent applications across Canada, US, and Europe, with 20 patents fully granted.

What diseases is Telo Genomics developing tests for?

Telo Genomics is developing diagnostic and prognostic tests for Multiple Myeloma, Minimal Residual Disease (MRD), early-stage Alzheimer's disease, and prostate cancer.

How long will the TeloViewSMM test patent protection last?

The TeloViewSMM test for smoldering myeloma will have patent protection until 2043.